secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2024-02-13T23:59:59+00:00
Accession:  0000875045-24-000004
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biogen Q4 revenue $2.4B, GAAP EPS $1.71; 2024 Non-GAAP EPS guidance $15-$16
---------------------------------------------------------------------------

- Q4 2023 revenue $2.4B (-6% YoY); GAAP EPS $1.71 vs $3.79; Non-GAAP EPS $2.95 vs $4.05
- Full year 2023 revenue $9.8B (-3% YoY); GAAP EPS $7.97 vs $20.87; Non-GAAP EPS $14.72 vs $17.67
- EPS negatively impacted by $0.35 from ADUHELM closeout costs; LEQEMBI co-promotion announced
- 2024 guidance: Non-GAAP EPS $15.00-$16.00 (~5% growth vs 2023); revenue expected down low- to mid-single digit
- SKYCLARYS launched with ~1,000 patients; ZURZUVAE postpartum depression launch; 'Fit for Growth' $1B gross savings by 2025

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000087504524000004/0000875045-24-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000087504524000004/biib-20240213.htm
  HTML page:      https://secwatch.observer/filing/0000875045-24-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer